Opticyte
Opticyte develops the VitalO₂ device, a medical device that provides real-time measurement of cellular and blood oxygen levels to help clinicians detect and treat sepsis, trauma, and respiratory failure. Its technology is designed to deliver accurate results for all skin tones, addressing disparities in current pulse oximetry and aiming to reduce organ failure and death. Opticyte's mission is to bring greater equity to healthcare and improve outcomes for critically ill patients.
Facts
- Sectors
- Medical device, Healthcare, Diagnostics
- Founded
- 2016 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- Opticyte Inc Seattle business license
- Total raised
- $72.3K SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $72.3K · Sep 2017 SEC Form D
- Founders
- Lori Arakaki, PhD
Is this your organization? Claim it
Opticyte sponsors Unite for Sepsis Symposium in Washington, DC; CEO Lori Arakaki to speak
Opticyte is sponsoring the second annual Unite for Sepsis Symposium in Washington, DC, where its CEO Lori Arakaki will be a featured speaker, joining clinicians and others focused on sepsis innovation.
Opticyte CEO Lori Arakaki to Speak at Sepsis Alliance’s Unite for Sepsis Symposium, Highlights Company’s Faster Sepsis-Detection Tools
Opticyte CEO Lori Arakaki will speak at the Unite for Sepsis Symposium, emphasizing the urgency of sepsis and the company’s work on tools to help clinicians detect it faster while highlighting the importance of awareness and advocacy.
Opticyte CEO Lori Arakaki Presents Cellular Oxygenation Monitor at MTEC Session During SCCM Critical Care Congress
Opticyte CEO Lori Arakaki presented at an MTEC-sponsored session during SCCM’s Critical Care Congress about Opticyte’s cellular oxygenation monitor and its potential to improve survival from battlefield trauma.
Opticyte’s VitalO2 Promises Noninvasive Cellular Oxygenation and Skin‑Tone‑Accurate Pulse Oximetry, Backed by CEO Lori Arakaki’s UW Research
Opticyte, led by CEO and bioengineer Lori Arakaki, is developing VitalO2, a noninvasive device that uses optical spectroscopy and machine learning to measure cellular oxygenation and provide accurate pulse oximetry across all skin tones, aiming to improve monitoring and care for critically ill patients.
Opticyte hosts June 11 webinar with CEO Lori Arakaki and Doug Baldwin Jr. on VitalO₂, pulse oximeter equity, and Vault89 investment
Opticyte invites readers to a June 11 live webinar where CEO Lori Arakaki and Doug Baldwin Jr. will discuss VitalO₂, equity in pulse oximetry accuracy, and Opticyte’s work to improve healthcare access and outcomes.
Opticyte Seeks Final Investors as StartEngine Campaign Nears Close after $235,000+ Raised; VitalO₂ Targets Earlier Hypoxia Detection and Racial Bias in Oximetry
Opticyte is in the final month of its StartEngine raise, having secured over $235,000 on the platform plus additional convertible-note investment, and is inviting new investors to support its VitalO₂ Monitor aimed at earlier oxygen deficiency detection and reducing pulse oximetry racial disparities.
Opticyte announces VitalO₂ Monitor wins two FDA Breakthrough Device designations for cellular oxygenation and equitable pulse oximetry
Opticyte highlights that its VitalO₂ Monitor, developed from over 30 years of research led by CEO Lori Arakaki, PhD, has earned two FDA Breakthrough Device designations for noninvasive cellular oxygenation monitoring and equitable pulse oximetry across all skin tones.
Opticyte announces VitalO2 Monitor delivers continuous, noninvasive cellular oxygen measurement clinicians say aids earlier detection of sepsis and organ failure
Opticyte’s VitalO2 Monitor provides continuous, noninvasive direct measurement of cellular oxygenation that clinicians say could enable earlier detection of sepsis, trauma, and respiratory failure to improve outcomes.
Opticyte highlights sepsis survivor crisis at World Sepsis Congress and promotes VitalO₂ for early detection
Opticyte CEO Lori Arakaki attended the World Sepsis Congress and highlights alarming survivor outcomes—high mortality, frequent long-term disability, and widespread discharge to long-term care—underscoring the company’s push to improve early sepsis detection with its VitalO₂ cell oxygen monitor.
Opticyte Announces Second FDA Breakthrough Device Designation for Pulse Oximetry, Adding to 2022 Cell O2 Award
Opticyte announces it received a second FDA Breakthrough Device Designation for its pulse oximetry technology, adding to a 2022 designation for its Cell O2 product and marking two breakthroughs for a single device. The company says the designation recognizes improved accuracy for patients with darker skin, will accelerate development, and advances healthcare equity while inviting investment via its StartEngine campaign.
People
-
Lori Arakaki Executive, CEO
